Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma (clinicaltrials.gov) - Oct 23, 2026 - P2 | N=40 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University
New P2 trial • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma
|